Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease
We are delighted to announce our collaboration with Lundbeck, a global pharmaceutical company specialized in brain diseases. We are working to provide a new model to develop drugs for devastating neurodegenerative movement disorders using the nematode worm C. elegans. The model, made by expressing human genes found in patients will enable Lundbeck to find new interventions which, like the disease, act during development.
Neurodegeneration produces behavioural changes with profound effects on quality of life that cannot be replicated in in vitro models. Testing compounds that could slow the degeneration of neurons in a mammalian model are limited by time, expense and regulation. Magnitude Biosciences use the nematode worm C. elegans to quickly generate models of neurodegenerative disease through overexpression of human proteins implicated in neurodegenerative diseases, which leads to loss of function phenotypes that can be scored and used to test interventions. Our automated data acquisition, robust methodology and processes help us conduct experiments quickly with high reproducibility. Lundbeck approached Magnitude Biosciences as a world- leading C. elegans CRO. This collaboration is an example that we can adapt to the needs of a wide range of disease-specific challenges in drug discovery.
“We are excited to be working with Magnitude Biosciences. Their unique approach to generating in vivo data for studying disease models will hopefully help us get fast and reliable answers to our research questions.”
– Kjartan Herrik, Principal Scientist at Lundbeck
Please look out for the results of this collaboration, which will be shared in the public domain.
Pharmaceutical company Lundbeck in collaboration with Magnitude Biosciences on innovative new platform to test interventions for neurodegenerative disease
Lundbeck collaborates with Magnitude on innovate platform to test neurodegenerative disease interven...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Magnitude Biosciences’ new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More
Get regular updates in your inbox
Sign up to our newsletter today, to get access to the latest company and industry news
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
